Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Protiva Biotherapeutics Inc.

Division of Arbutus Biopharma Corp.
www.protivabio.com

Latest From Vexim SAS

Medtechs At The Wheel In New Health Care Landscape

2016 was a year of surprise and change in political circles, but that's nothing new for the medtech industry, which over a number of years has become accustomed to health care systems demanding different and ever-higher levels of service. Smart medtechs have been ahead of the curve, but the whole industry now factors in clients' wider needs in a holistic approach to patient care. Many companies' current M&A policies are already reflecting the changes to come.

M & A Deals

OUS Approvals Analysis: BSX, Edwards Score New CE Marks In TAVR Battlefield; Chinese DES Advances In Asia

September's list of devices approved outside the US include a new transcatheter aortic valve in Europe, two orthopedic devices and a gynecology device in Australia, and a drug-eluting stent in Pakistan.

Research & Development Approvals

Medtech Execs On The Move, February 2014

Recent executive-level company changes and promotions in the medical device and diagnostics industries.

Medical Device

Device Firms See No Correlation Between Series A And Exit

Large or small, Series A rounds in the device sector don’t have a statistical correlation with exit value, but there is some evidence that initial runway has some influence.

Medical Device Deals
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Gene Therapy, Cell Therapy
    • Large Molecule
    • Liposomes
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
      • Site Specific
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • Canada
  • Parent & Subsidiaries
  • Arbutus Biopharma Corp.
  • Senior Management
  • Mark J Murray, PhD, Pres. & CEO
    Ian McLachlan, PhD, CSO
  • Contact Info
  • Protiva Biotherapeutics Inc.
    Phone: (604) 630-5061
    100-3480 Gilmore Way
    Burnaby, V5G 4W7
    Canada
Advertisement
Advertisement
UsernamePublicRestriction

Register